Sibylle Neuhoff

4.1k citations

68 papers · 2.8k indexed · h-index 30

Pharmacology top 0.2%
- Pharmacogenetics and Drug Metabolism 30
Pharmaceutical Science top 1%
- Drug Solubulity and Delivery Systems 7
Oncology top 2%
- Drug Transport and Resistance Mechanisms 54
Pediatrics, Perinatology and Child Health top 1%
- Pharmacological Effects and Toxicity Studies 26
Spectroscopy top 5%
- Analytical Chemistry and Chromatography 7
Epidemiology
- Liver Disease Diagnosis and Treatment 7
Infectious Diseases
- HIV/AIDS drug development and treatment 5
Biochemistry
- Amino Acid Enzymes and Metabolism 4

Co-authors: Amin Rostami‐Hodjegan Masoud Jamei Per Artursson Ismael Zamora Anna‐Lena Ungell David B. Turner Matthew D. Harwood Geoffrey T. Tucker
Cited by: Pharmacology Pharmaceutical Science Oncology
Journals: Clinical Pharmacology & Therapeutics (10 papers)CPT Pharmacometrics & Systems Pharmacology (10 papers)Journal of Pharmaceutical Sciences (6 papers)
Partner nations: United Kingdom United States Sweden

In The Last Decade

Sibylle Neuhoff

65 papers receiving 2.8k citations

Peers

Countries citing papers authored by Sibylle Neuhoff

Since Specialization

Citations

This map shows the geographic impact of Sibylle Neuhoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sibylle Neuhoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sibylle Neuhoff more than expected).

Fields of papers citing papers by Sibylle Neuhoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sibylle Neuhoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sibylle Neuhoff. The network helps show where Sibylle Neuhoff may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sibylle Neuhoff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sibylle Neuhoff Line = papers co-authored together Sibylle Neuhoff links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability‐Limited Multicompartment Liver Model CPT Pharmacometrics & Systems Pharmacology ·William A. Murphy,Noora Sjöstedt,Maïlys De Sousa Mendes,John Chambers,Kim L. R. Brouwer,Sibylle Neuhoff	2025	0
2	A Bottom-up Approach for Mutant and Wild Type Collies Using Physiologically Based Pharmacokinetic (PBPK) Modeling: A Case Study Using Loperamide The AAPS Journal ·C E Cross,Marilyn N. Martinez,Liangchen Zhu,Michael J. Myers,Sibylle Neuhoff	2025	0
3	A guide to developing population files for physiologically‐based pharmacokinetic modeling in the Simcyp Simulator CPT Pharmacometrics & Systems Pharmacology ·Da-wang Tang,Bei-Cheng Qu,Frédéric Y. Bois,Ruth M. Clayton,Eman El‐Khateeb,Trevor N. Johnson,Muhammad Faisal,Sibylle Neuhoff,Charles D. Gazzola,Amin Rostami‐Hodjegan	2024	5
4	Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD Hepatology Communications ·William A. Murphy,Anna Mae Diehl,Matthew Shane Loop,Dong Fu,Cynthia D. Guy,Manal F. Abdelmalek,Georgia Sofia Karachaliou,Noora Sjöstedt,Sibylle Neuhoff,Paavo Honkakoski,Kim L. R. Brouwer	2024	7
5	Performance Verification of CYP2C19 Enzyme Abundance Polymorphism Settings within the Simcyp Simulator v21 Metabolites ·R. E. Rapley,Iain Gardner,Sandra Köberl-Jelovcan,空気調和衛生工学会スタンダード委員会,Sibylle Neuhoff,Vidya Perera,José Luis Río,Brian J. Schmidt,Lu Gaohua	2022	6
6	Prediction of CYP‐mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator CPT Pharmacometrics & Systems Pharmacology ·Peter Kilford,Adekunle Adeoye,S. Ya. Golosovker,Iain Gardner,Oliver Hatley,Alice Ke,Sibylle Neuhoff,John Pickles,Karen Rowland Yeo	2022	32
7	In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition The AAPS Journal ·千佳大木,Sibylle Neuhoff,Amin Rostami‐Hodjegan,Hiroyuki Takita,Zubida M. Al‐Majdoub,Kayode Ogungbenro	2022	16
8	Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective Clinical Pharmacology & Therapeutics ·Kunal S. Taskar,Xinning Yang,Sibylle Neuhoff,Mitesh Patel,Kenta Yoshida,Mary F. Paine,Kim L. R. Brouwer,Xiaoyan Chu,Yuichi Sugiyama,Jack Cook,Joseph W. Polli,Imad Hanna,Yurong Lai,Maciej J. Zamek‐Gliszczynski,(unknown)	2022	23
9	Comparison of Canine and Human Physiological Factors: Understanding Interspecies Differences that Impact Drug Pharmacokinetics The AAPS Journal ·Marilyn N. Martinez,Jonathan P. Mochel,Sibylle Neuhoff,Liangchen Zhu	2021	24
10	Application of proteomic data in the translation of in vitro observations to associated clinical outcomes Drug Discovery Today Technologies ·Sibylle Neuhoff,Matthew D. Harwood,Amin Rostami‐Hodjegan,Brahim Achour	2021	8
11	Intestinal P‐gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications Clinical Pharmacology & Therapeutics ·Maciej J. Zamek‐Gliszczynski,Mitesh Patel,Xinning Yang,Justin D. Lutz,Xiaoyan Chu,Kim L. R. Brouwer,Yurong Lai,Caroline A. Lee,Sibylle Neuhoff,Mary F. Paine,Yuichi Sugiyama,Kunal S. Taskar,Aleksandra Galetin	2020	39
12	Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models Journal of Pharmaceutical Sciences ·博之井奥,Thủy Đoàn Thanh,Alexandra Crowe,Qiang Liu,Sonia Pahwa,Khondoker Alam,Sibylle Neuhoff,Oliver Hatley,Kai Ding,Wei Yue	2020	9
13	A Laboratory-Specific Scaling Factor to Predict the In Vivo Human Clearance of Aldehyde Oxidase Substrates Drug Metabolism and Disposition ·Maïlys De Sousa Mendes,D. A. PISANENKO,O. A. Bukin,Barry Jones,Iain Gardner,Sibylle Neuhoff,Venkatesh Pilla Reddy	2020	14
14	Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport Journal of Pharmaceutical Sciences ·Sonia Pahwa,Khondoker Alam,Alexandra Crowe,Thủy Đoàn Thanh,Sibylle Neuhoff,Oliver Hatley,Kai Ding,Wei Yue	2017	42
15	Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs The AAPS Journal ·Rachel H. Rose,David B. Turner,Sibylle Neuhoff,Masoud Jamei	2017	22
16	In Vitro–In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition Drug Metabolism and Disposition ·Matthew D. Harwood,Brahim Achour,Sibylle Neuhoff,Matthew R. Russell,Gordon Carlson,G. Warhurst,Amin Rostami‐Hodjegan	2016	36
17	Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis Drug Metabolism and Disposition ·Howard Burt,Arian Emami Riedmaier,Matthew D. Harwood,H.K. Crewe,Katherine L. Gill,Sibylle Neuhoff	2016	59
18	Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: Estimating time varying CSF drug concentrations and their variability using in vitro data Drug Metabolism and Pharmacokinetics ·Lu Gaohua,Sibylle Neuhoff,Trevor N. Johnson,Amin Rostami‐Hodjegan,Masoud Jamei	2016	62
19	In Vitro–In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells Drug Metabolism and Disposition ·Matthew D. Harwood,Brahim Achour,Sibylle Neuhoff,Matthew R. Russell,Gordon Carlson,G. Warhurst,(unknown)	2015	50
20	Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites International Journal of Clinical Pharmacology and Therapeutics ·Sibylle Neuhoff,Peter Langguth,D. A. L. Smout,Tommy B. Andersson,C G Regårdh,H. Spahn‐Langguth	2000	45

About Sibylle Neuhoff

Sibylle Neuhoff is a scholar working on Pharmacology, Oncology, Pediatrics, Perinatology and Child Health, Pharmaceutical Science and Biochemistry, having authored 68 papers that have together received 2.8k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (54 papers), Pharmacogenetics and Drug Metabolism (30 papers), Pharmacological Effects and Toxicity Studies (26 papers), Analytical Chemistry and Chromatography (7 papers), Liver Disease Diagnosis and Treatment (7 papers), Drug Solubulity and Delivery Systems (7 papers), HIV/AIDS drug development and treatment (5 papers) and Amino Acid Enzymes and Metabolism (4 papers). The work is most often cited by research in Pharmacology (968 citations), Pharmaceutical Science (404 citations), Oncology (1.6k citations), Pediatrics, Perinatology and Child Health (794 citations) and Spectroscopy (331 citations). Sibylle Neuhoff has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include Amin Rostami‐Hodjegan, Masoud Jamei, Per Artursson, Ismael Zamora, Anna‐Lena Ungell, David B. Turner, Matthew D. Harwood, Geoffrey T. Tucker, Sebastian Polak and Jiansong Yang. Their work appears in journals such as Clinical Pharmacology & Therapeutics, CPT Pharmacometrics & Systems Pharmacology, Journal of Pharmaceutical Sciences, The AAPS Journal and Drug Metabolism and Disposition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact